Pharming Group N.V. announces that the European Commission has granted marketing authorization for Joenja (leniolisib)
[출처/시간] Briefing.com - 3:34 PM ET, 05/22/2026 Joenja is an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, for the treatment of activated PI3K delta syndrome, a rare primary immunodeficiency, in adult and pediatric patients 12 years of age and older. Joenja is the first and only approved treatment for APDS in the European Union.The first European launch is expected in Germany in Q3 2026, with additional launches anticipated pen
[출처/시간] Briefing.com - 3:34 PM ET, 05/22/2026
Joenja is an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, for the treatment of activated PI3K delta syndrome, a rare primary immunodeficiency, in adult and pediatric patients 12 years of age and older. Joenja is the first and only approved treatment for APDS in the European Union.The first European launch is expected in Germany in Q3 2026, with additional launches anticipated pending completion of national reimbursement negotiations.
당신의 반응은 무엇인가요?
좋아요
0
싫어요
0
사랑
0
재미있는
0
화난
0
슬프다
0
와우
0
